🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 15 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 23/03/1998 | 16,38 | 17,19 | 16,25 | 16,50 | +0,76% | 5,73% | 620.600 |
| 20/03/1998 | 16,81 | 16,88 | 16,25 | 16,38 | -2,42% | 3,72% | 397.800 |
| 19/03/1998 | 17,13 | 17,31 | 16,75 | 16,78 | -3,07% | 3,28% | 250.600 |
| 18/03/1998 | 17,19 | 17,50 | 17,06 | 17,31 | -1,07% | 2,55% | 288.000 |
| 17/03/1998 | 17,38 | 17,56 | 17,13 | 17,50 | -0,18% | 2,52% | 391.200 |
| 16/03/1998 | 17,63 | 17,63 | 17,31 | 17,53 | +0,18% | 1,77% | 320.600 |
| 13/03/1998 | 17,13 | 17,56 | 17,13 | 17,50 | +1,45% | 2,55% | 407.800 |
| 12/03/1998 | 17,13 | 17,25 | 16,88 | 17,25 | +1,66% | 2,19% | 87.600 |
| 11/03/1998 | 17,63 | 17,63 | 16,88 | 16,97 | -3,04% | 4,26% | 255.600 |
| 10/03/1998 | 17,38 | 17,56 | 17,19 | 17,50 | +0,72% | 2,16% | 139.400 |
| 09/03/1998 | 17,25 | 17,50 | 17,00 | 17,38 | -0,36% | 2,90% | 325.200 |
| 06/03/1998 | 17,50 | 17,81 | 17,25 | 17,44 | -0,36% | 3,21% | 564.400 |
| 05/03/1998 | 17,50 | 17,81 | 17,50 | 17,50 | -3,11% | 1,79% | 291.200 |
| 04/03/1998 | 18,13 | 18,31 | 17,75 | 18,06 | -1,70% | 3,10% | 163.800 |
| 03/03/1998 | 18,50 | 18,50 | 18,13 | 18,38 | +0,34% | 2,03% | 130.400 |
| 02/03/1998 | 18,38 | 18,75 | 18,13 | 18,31 | -2,01% | 3,40% | 348.800 |
| 27/02/1998 | 18,00 | 18,94 | 18,00 | 18,69 | +2,40% | 5,21% | 340.000 |
| 26/02/1998 | 18,00 | 18,38 | 17,91 | 18,25 | +1,04% | 2,60% | 616.800 |
| 25/02/1998 | 18,31 | 18,31 | 17,91 | 18,06 | -1,20% | 2,22% | 281.800 |
| 24/02/1998 | 18,59 | 18,63 | 18,13 | 18,28 | -1,85% | 2,69% | 422.000 |
| 23/02/1998 | 18,88 | 19,06 | 18,50 | 18,63 | -0,67% | 2,98% | 906.600 |
| 20/02/1998 | 18,75 | 18,86 | 18,38 | 18,75 | -0,33% | 2,58% | 114.400 |
| 19/02/1998 | 18,63 | 19,06 | 18,50 | 18,81 | +0,33% | 3,02% | 1.208.800 |
| 18/02/1998 | 18,63 | 19,31 | 18,63 | 18,75 | -1,32% | 3,69% | 450.600 |
| 17/02/1998 | 19,00 | 19,53 | 18,44 | 19,00 | +0,00% | 5,76% | 577.200 |
| 13/02/1998 | 18,31 | 19,19 | 17,88 | 19,00 | +4,83% | 7,17% | 551.400 |
| 12/02/1998 | 18,13 | 18,31 | 17,56 | 18,13 | +0,35% | 4,14% | 646.600 |
| 11/02/1998 | 18,00 | 18,06 | 17,75 | 18,06 | +0,35% | 1,74% | 278.000 |
| 10/02/1998 | 18,13 | 18,25 | 17,75 | 18,00 | +1,05% | 2,76% | 307.400 |
| 09/02/1998 | 18,13 | 18,38 | 17,75 | 17,81 | -1,64% | 3,45% | 238.200 |